|
1) United Network for organ sharing. http://www.unos.org/(2011. 7. 1確認)
|
|
|
|
|
2) 日本肝移植研究会. 肝移植症例登録報告. 移植. 2010; 45: 621
|
|
|
|
|
3) 日本臓器移植ネットワーク・ホームページ. http://www.jotnw.or.jp/(2011. 7. 1確認)
|
|
|
|
|
|
4) 川崎誠治, 石崎陽一. 脳死肝移植の現状と展望. 日消病会誌. 2011; 108: 717
|
|
|
|
|
5) Segev DV, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008; 14: 512-25
|
|
|
|
|
6) Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int. 2009; 22: 892-905
|
|
|
|
|
|
7) Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation. 2010; 90: 1204-9
|
|
|
|
|
|
8) Berenguer M, Royuela A, Zamora J. Immunosuppression with cacineurin inhibitors with respect to the outcomes of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007; 13: 21-9
|
|
|
|
|
|
9) Rayhill SC, Wo YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation. 2007; 84: 331-9
|
|
|
|
|
|
10) Lai JC, Verna EC, Brown RS, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011; Apr 28 [Epub ahead of print]
|
|
|
|
|
|
11) Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl. 2009; 15: 1126-32
|
|
|
|
|
|
12) Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to pet-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010; 139: 1577-85
|
|
|
|
|
|
13) Mas V, Maluf D, Archer KJ, et al. Transcription at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl. 2011; 17: 824-35
|
|
|
|
|
|
14) Brown RS Jr. Live donors in liver transplantation. Gastroenterology. 2008; 134; 1802-13
|
|
|
|
|
|
15) Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011; 17: 528-38
|
|
|
|
|
|
16) Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746-56
|
|
|
|
|
|
17) Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008; 14: 53-8
|
|
|
|
|
|
18) D'Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl. 2009; 15: 1278-87
|
|
|
|
|
|
19) Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25: 310-2
|
|
|
|
|
|
20) Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007; 13: 1637-44
|
|
|
|
|
|
21) Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009; 87: 531-7
|
|
|
|
|
|
22) Todo S, Furukawa H, Tada M, et al. Extending indication: Role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2007; 13: S48-54
|
|
|
|
|
|
23) Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009; 49: 832-8
|
|
|
|
|
|
24) Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010; 10: 129-37
|
|
|
|
|
|
25) Yao FY, Kerlan RK Jr. Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48: 819-27
|
|
|
|
|
|
26) Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: Results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2007; 132; 1746-56
|
|
|
|
|
|
27) Egawa H, Taira K, Teramukai S, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: A single center experience. Dig Dis Sci. 2009; 54: 1347-54
|
|
|
|
|
|
28) Egawa H, Ueda Y, Ichida T, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transpl. 2011; 11: 518-27
|
|
|
|
|
|
29) Yi NJ, Suh KS, Lee HW, et al. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl. 2009; 15: 496-503
|
|
|
|
|
|
30) Ikegami T, Masuda Y, Ohio Y, et al. Prognosis of adult patients transplanted with liver grafts ＜35% of their standard liver volume. Liver Transpl. 2009; 15: 1622-30
|
|
|
|
|
|
31) Taketomi A, Kayashima H, Soejima Y, et al. Donor risk in adult-to-adult living donor liver transplantation: impact of left lobe graft. Transplantation. 2009; 87: 445-50
|
|
|
|
|
|
32) Botha JF, Langnas AN, Campos BD, et al. Left lobe adult-to-adult living donor liver transplantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome. Liver Transpl. 2010; 16: 649-57
|
|
|
|
|
|
33) Yamada T, Tanaka K, Uryuhara K, et al. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. Am J Transpl. 2008; 8: 847-53
|
|
|
|
|
|
34) Ogura Y, Hori T, EI Moghazy WM, et al. Portal pressure ＜ 15 mmHg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl. 2010; 16: 718-28
|
|
|
|
|
|
35) Konishi N, Ishizaki Y, Sugo H, et al. Impact of a left-lobe graft without modulation of portal flow in adult-to-adult living donor liver transplantation. Am J Transplant. 2008; 8: 170-4
|
|
|
|
|